Rxivist logo

Effectiveness of Ivermectin-Based Multidrug Therapy in Severe Hypoxic Ambulatory COVID-19 Patients

By Sabine Hazan, Sonya Dave, Anoja W. Gunaratne, Sibasish Dolai, Peter A McCullough, Robert Clancy, Thomas J Borody

Posted 07 Jul 2021
medRxiv DOI: 10.1101/2021.07.06.21259924

Ivermectin is a safe, inexpensive and effective early COVID-19 treatment validated in 20+ RCTs. Having developed combination therapies for Helicobacter pylori, we tested various COVID-19 combinations and describe the most effective. In 24 consecutive COVID-19 subjects with high risk features, hypoxia and untreated moderate-severe symptoms averaging 9 days, we trialed this novel combination comprising ivermectin, doxycycline, zinc, and Vitamins D and C. It was highly effective. All subjects resolved symptoms in 11 days on average, and oxygen saturation improved in 24hrs (87.4% to 93.1%, p=0.001). Hospitalizations and deaths were significantly fewer (p<0.002 or 0.05, respectively) than in background-matched controls from the CDC database. Triple combination therapy is safe and effective even in moderate-severe patients with hypoxia treated in the outpatient setting.

Download data

  • Downloaded 11,791 times
  • Download rankings, all-time:
    • Site-wide: 868
    • In infectious diseases: 281
  • Year to date:
    • Site-wide: 251
  • Since beginning of last month:
    • Site-wide: 137

Altmetric data

Downloads over time

Distribution of downloads per paper, site-wide